Revvity, Inc.
- Last sale
- Nov 12, 2026 · -0.78%
- Market cap
- $17.53B
- 111.64M shares
- Filings
- 1,031
Q3 2026+3.7% FY25 yoy
Q3 2026−10.8% FY25 yoy
Q3 2026+2.9% FY25 yoy
Q3 2026derived−6.0% FY25 yoy
Q3 2026−5.9% FY25 yoy
Q3 2026−20.9% FY25 yoy
- $17.53B
- 69.2×
- 6.0×
- 2.4×
- 3.37%
- 0.18%
Twelve months to Oct 4, 2026 · derived
Price
Nov 12, 2026 · IEX last sale
IEX last saleClose of recordAs traded
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Revenue
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2025-12-28 | $2,856,051,000 | reported | |
| FY 2024 | 2024-12-29 | $2,755,026,000 | reported | |
| FY 2023 | 2023-12-31 | $2,750,571,000 | reported | |
| FY 2022 | 2023-01-01 | $3,311,822,000 | reported | |
| FY 2021 | 2022-01-02 | $3,827,808,000 revised | reported | |
| FY 2020 | 2021-01-03 | $2,663,230,000 revised | reported | |
| FY 2019 | 2019-12-29 | $2,883,673,000 | reported | |
| FY 2018 | 2018-12-30 | $2,777,996,000 | reported | |
| FY 2017 | 2017-12-31 | $2,256,982,000 | reported | |
| FY 2016 | 2017-01-01 | $2,115,517,000 | reported | |
| FY 2015 | 2016-01-03 | $2,104,823,000 revised | reported | |
| FY 2014 | 2014-12-28 | $2,237,219,000 revised | reported |
Capital returns
| Fiscal year | Dividends | Buybacks | Total | Per share | Shares | Shares · yoy | of free cash flow |
|---|---|---|---|---|---|---|---|
| FY2025 | $32.80M | $820.82M | $853.62M | $0.28 | 111.80M sh | −7.0% | 167.6% |
| FY2024 | $34.45M | $369.58M | $404.03M | $0.28 | 120.19M sh | −2.7% | 74.6% |
| FY2023 | $34.97M | $388.88M | $423.85M | $0.28 | 123.53M sh | −2.3% | 4279.6% |
| FY2022 | $35.34M | $80.64M | $115.98M | $0.28 | 126.41M sh | +0.2% | 19.5% |
| FY2021 | $32.37M | $73.07M | $105.45M | — | 126.18M sh | +12.6% | 8.0% |
Segments
LineFY2025ShareChange
Life Sciences$1.43B50%+2.3%
Diagnostics$1.42B50%+5.1%
Diagnostics———
Discovery & Analytical Solutions———
Life Sciences———
Total$2.86B
Laboratory analytical instruments
Revvity, Inc. is the 7th largest of the 25 covered companies the SEC files under this code, by revenue. SIC 3826
CompanyRevenueGrowthNet marginMarket cap
AAgilent Technologies, Inc.$6.9B6.7%18.8%$48.8BAVTRAvantor, Inc.$6.6B3.4%8.1%$10.8BILMNIllumina, Inc.$4.3B0.7%19.6%$31.7BMTDMettler Toledo International Inc$4.0B4.0%21.6%$34.4BBRKRBruker Corp$3.4B2.1%0.3%$9.2BWATWaters Corp$3.2B7.0%20.3%$45.4B
RVTYRevvity, Inc. (this company)$2.9B3.7%8.4%$17.5B
BIOBio-Rad Laboratories, Inc.$2.6B0.7%29.4%$9.6BTXG10x Genomics, Inc.$642.8M5.2%6.8%$7.5BPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
Revvity, Inc. · CIK 31791 · Engraved from SEC EDGAR